SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 190.46 |
Enterprise Value ($M) | 102.58 |
Book Value ($M) | 91.02 |
Book Value / Share | 0.73 |
Price / Book | 2.09 |
NCAV ($M) | 86.98 |
NCAV / Share | 0.69 |
Price / NCAV | 2.19 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.38 |
Return on Assets (ROA) | -0.30 |
Return on Equity (ROE) | -0.30 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 17.33 |
Current Ratio | 17.61 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 92.22 |
Assets | 96.25 |
Liabilities | 5.24 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -31.38 |
Net Income | -34.44 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -20.94 |
Cash from Investing | -0.01 |
Cash from Financing | -1.48 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
196,757 | 878,906 | 22.39 | |
193,795 | 804,198 | 24.10 | |
431,490 | 2,338,056 | 18.46 | |
278,493 | 163,307 | 170.53 | |
137,217 | 209,758 | 65.42 | |
(click for more detail) |
Similar Companies | |
---|---|
ASNS – Actelis Networks, Inc. | ASRT – Assertio Holdings, Inc. |
ATNF – 180 Life Sciences Corp. | ATXI – Avenue Therapeutics, Inc. |
AVTX – Avalo Therapeutics, Inc. |